Whilst confirming that activation of the PI3K-AKT-mTOR pathway results in an increased glycolytic phenotype, we have also demonstrated a specific dependence for PIK3CA mutated cells on glucose and illustrated that targeting this pathway offers therapeutic potential and tumour imaging insight. This evidence concerns the gene MTOR and neoplasm.